Sydney L. Rosenblum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sydney L. Rosenblum has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Lee Garner
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States
2 shared publications - Aaron Morgan Leconte
W.M. Keck Science Department of Claremont McKenna, Pitzer, and Scripps Colleges
1 shared publication - Alexander Pasternak
Discovery Chemistry, Merck & Co., Inc., Boston, MA 02115, USA
1 shared publication Alexie L. Ogonowsky
W. M. Keck Science Department, Claremont McKenna, Pitzer, and Scripps Colleges, Claremont, CA, 91711, USA
1 shared publicationAurora G. Weiden
W. M. Keck Science Department, Claremont McKenna, Pitzer, and Scripps Colleges, Claremont, CA, 91711, USA
1 shared publicationDalia M. Soueid
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 1600 Huron Parkway, NCRC B520, Ann Arbor, MI 48109, USA
1 shared publication
Latest Publications
- Open Access
- 19 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (5) , 1539-1546
Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA–protein interaction
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.
- 19 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (5) , 1539-1546
Open AccessLive cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA–protein interaction
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.
- Open Access
- 8 December 2020
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 2 (1) , 241-247
A live-cell assay for the detection of pre-microRNA–protein interactions
Leveraging bioorthogonal chemistry- and split-luciferase assay technologies, we have devised a new assay for the live-cell detection of RNA–protein interactions, RNA interaction with Protein-mediated Complementation Assay or RiPCA.
- 8 December 2020
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 2 (1) , 241-247
Open AccessA live-cell assay for the detection of pre-microRNA–protein interactions
Leveraging bioorthogonal chemistry- and split-luciferase assay technologies, we have devised a new assay for the live-cell detection of RNA–protein interactions, RNA interaction with Protein-mediated Complementation Assay or RiPCA.
- 7 April 2017
- Published by Wiley in ChemBioChem
- Vol. 18 (8) , 816-823
Design and Discovery of New Combinations of Mutant DNA Polymerases and Modified DNA Substrates
Chemical modifications can enhance the properties of DNA by imparting nuclease resistance and generating more‐diverse physical structures. However, native DNA polymerases generally cannot synthesize significant lengths of DNA with modified nucleotide triphosphates. Previous efforts have identified a mutant of DNA polymerase I from Thermus aquaticus DNA (SFM19) as capable of synthesizing a range of short, 2′‐modified DNAs; however, it is limited in the length of the products it can synthesize. Here, we rationally designed and characterized ten mutants of SFM19. From this, we identified enzymes with substantially improved activity for the synthesis of 2′F‐, 2′OH‐, 2′OMe‐, and 3′OMe‐modified DNA as well as for reverse transcription of 2′OMe DNA. We also evaluated mutant DNA polymerases previously only tested for synthesis for 2′OMe DNA and showed that they are capable of an expanded range of modified DNA synthesis. This work significantly expands the known combinations of modified DNA and Taq DNA polymerase mutants.
- 7 April 2017
- Published by Wiley in ChemBioChem
- Vol. 18 (8) , 816-823
Design and Discovery of New Combinations of Mutant DNA Polymerases and Modified DNA Substrates
Chemical modifications can enhance the properties of DNA by imparting nuclease resistance and generating more‐diverse physical structures. However, native DNA polymerases generally cannot synthesize significant lengths of DNA with modified nucleotide triphosphates. Previous efforts have identified a mutant of DNA polymerase I from Thermus aquaticus DNA (SFM19) as capable of synthesizing a range of short, 2′‐modified DNAs; however, it is limited in the length of the products it can synthesize. Here, we rationally designed and characterized ten mutants of SFM19. From this, we identified enzymes with substantially improved activity for the synthesis of 2′F‐, 2′OH‐, 2′OMe‐, and 3′OMe‐modified DNA as well as for reverse transcription of 2′OMe DNA. We also evaluated mutant DNA polymerases previously only tested for synthesis for 2′OMe DNA and showed that they are capable of an expanded range of modified DNA synthesis. This work significantly expands the known combinations of modified DNA and Taq DNA polymerase mutants.